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of analyses conducted on fragments of the DMD and aPC 
genes correspond completely (100 %) with the results of 
previous studies. C-HrM sensitivity in Cnv detection was 
assessed through the analysis of mixed Dna samples with 
different proportions of a deletion carrier and wild type 
control. the results are presented as a linear regression 
with R2 of 0.9974 and imply the capability of the method to 
detect mosaics. C-HrM is an attractive and powerful alter-
native to other methods of point mutations and Cnv detec-
tion with 100 % accuracy in our studied group.
Introduction
Hereditary diseases are conditioned by small scale muta-
tions (including point mutations and sequence changes 
concerning only few nucleotides such as small insertions, 
deletions, inversions) and the rearrangements of larger 
genome fragments known as copy number variations 
(Cnvs) (arlt et al. 2012; Beckmann et al. 2008; Hastings 
et al. 2009; Henrichsen et al. 2009). One of the challenges 
of contemporary molecular studies is the efficient and cost-
effective detection of both types of changes in the genetic 
material (ladabaum et al. 2011). the methods that are cur-
rently, widely used require separate analyses to detect small 
mutations and large rearrangements. a method enabling a 
simultaneous analysis of both of these types of mutations 
would provide new possibilities for studies of molecular 
predisposition to hereditary diseases. Here we present com-
parative-high resolution melting (C-HrM), a new approach 
to simultaneous screening for small mutations and Cnvs.
to establish and evaluate the C-HrM method we have 
used Dna from two groups: familial adenomatous poly-
posis (FaP, MIM 175100) patients and families with diag-
nosed cases of Duchenne muscular dystrophy (DMD, MIM 
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310200). Both these disorders are characterized by a signif-
icant percentage of Cnv mutations in the disease-causing 
gene. DMD is caused by mutation in the dystrophin gene 
(DMD, MIM 300377) and belongs to X-linked disorders 
(Bakker et al. 1987; Oshima et al. 2009; tuffery-Giraud 
et al. 2009; White et al. 2006; White and den Dunnen 
2006). Changes in the adenomatous polyposis coli gene 
(APC, MIM 61173) are responsible for FaP, an autosomal 
dominant disease (aretz et al. 2005; Fang et al. 2011; Gro-
den et al. 1991; stekrova et al. 2007).
this approach was developed on the basis of the standard 
high resolution melting (HrM) screening method based on 
the analysis of amplified Dna fragments during the melt-
ing process by the presence of a fluorescent dye, intercalat-
ing double stranded Dna, in a reaction mixture (liew et al. 
2004; Wittwer 2009; Wittwer et al. 2003). Our new C-HrM 
method has the advantage over the standard HrM that 
besides screening for small mutations it enables, at the same 
time, the detection of large sequence changes such as ampli-
fications and deletions based on the melting peak height 
ratio in the multiplex reaction. Measurements of the fluores-
cence level obtained during the melting of amplified frag-
ments may be expressed as a derivative of the fluorescence 
change in time, making it possible to present the products 
in a reaction mixture in the form of peaks. each peak cor-
responds to a PCr product (or a product melting domain) 
present in a reaction mixture, and the peak height represents 
its relative amount. Our studies showed that it is possible to 
distinguish samples with large deletion from wild types on 
the basis of the peak height ratio in a multiplex reaction. We 
decided to use this observation and employ it in the simulta-
neous analysis of small mutations and Cnvs.
Materials and methods
Dna samples
We used Dna samples from 50 individuals from DMD 
families (where the DMD gene mutations were studied) 
and 50 probands diagnosed with FaP (where the APC 
gene mutations were studied) (Kwiatkowska et al. 1997; 
lisiecka et al. 1998; Plawski et al. 2004, 2007; Plawski and 
slomski 2008). a control group of 72 randomly selected 
unaffected individuals (36 women and 36 men) from the 
population was also examined. the studies were approved 
by the local ethics Committee of the Poznan University 
of Medical science and performed after obtaining written 
informed consent from all patients and control individuals.
Dna samples of all the patients involved in the veri-
fication of the method had been previously tested for 
the presence of small mutations using screening meth-
ods such as single strand conformation polymorphism 
(ssCP), heteroduplex analysis (Ha), high resolution melt-
ing (HrM), direct sequencing, and also multiplex ligation 
probe-dependent amplification (MlPa) to detect Cnvs 
(schouten et al. 2002; Zielenski et al. 2002). Our study 
included patients whose gene fragments (or entire genes) 
had undergone large rearrangements as well as those in 
which small mutations had been detected.
all patients’ samples were blinded for the purpose of 
method evaluation. analyses were performed on groups 
of 16 samples, out of whom 12 were randomly selected 
patients and the remaining 4 were control wild type sam-
ples. each sample was analysed in this manner in three 
separate analyses.
the validation of the C-HrM method for the DMD gene 
involved the analysis of exons 9, 45 and 49. the validation 
for the APC gene included an amplicon for the fragment of 
exon 15 including nucleotides 2802–2805 (which is one of 
the hot spots for APC gene mutations) and the amplicons 
covering parts of exons 9 and 14.
C-HrM primers
We designed sets of primers for a simultaneous amplifica-
tion of a reference fragment (with an unchanged number of 
copies) and a target fragment (with the DMD or APC gene 
fragments as its template). Designed primers for the DMD 
gene (exons 9, 45 and 49) and the APC gene (fragments of 
exons 9, 14 and 15) include large rearrangements and also 
small sequence changes detected in our group of patients. 
the conserved noncoding sequences of the albumin gene 
(ALB MIM 103600) localized at 4q13.3 and the lactate 
dehydrogenase B gene (LDHB MIM 150100) localized at 
12p12.1 were used as templates for reference fragments. 
Primers were designed using the Primer3plus (www.
bioinformatics.nl/primer3plus/) software. the melting tem-
perature of all primers was in the range of 58.0–62.3 °C 
(table 3).
subsequently, the primer pairs were selected for a multi-
plex reaction, with one of the products including the target 
fragment of the studied gene and the second one as a ref-
erence. amplicons were paired in respect of their melting 
temperature ranges (no overlaps between the amplicons) 
and lack of non-specific interactions between primers that 
could impair the amplification efficiency. attention was 
also paid to the size of each product (length of both ampli-
cons was similar), since smaller amplicons tend to amplify 
with higher efficiency. sequences of primers and matched 
pairs are collated in table 3.
assay design
the products were amplified using the type-it HrM kit 
(Qiagen) on the Dna templates at a concentration of 
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50 ng/μl diluted in ae buffer (Qiagen). the analysis was 
performed on a rotor-Gene® Q equipment (Qiagen). PCr 
reactions were carried out for the 30 cycles (with a 5 min 
preincubation at 95 °C) of 95 °C for 10 s, 55 °C for 30 s 
and 72 °C for 10 s, the products were then melted and PCr 
was continued to the 40th cycle in the same conditions fol-
lowed by another melting process. the first melting analy-
sis was performed from 70 °C to 90 °C by raising the tem-
perature by 0.3° at each step after which the second one, 
designed to detect small changes in the sequence, was car-
ried out with higher resolution raising the temperature by 
0.1° at each step.
Data interpretation and presentation of the results
the outline of the method is presented in Fig. 1. the result 
of the first Dna melting process (after the 30th cycle) 
of wild type samples is a characteristic pattern of a peak 
height corresponding to both the reference amplicon and 
the analysed amplicon (in Fig. 1a, green curve). In the 
case of samples with rearrangements the peak pattern is 
distorted. When one of the alleles of the analysed frag-
ment undergoes deletion, its peak decreases and, at the 
same time, the peak of the reference amplicon increases 
(Fig. 1a, red curve). the situation is reversed in the case 
of amplification, with the peak of the reference amplicon 
decreasing and the peak of the analysed amplicon increas-
ing (Fig. 1a, blue curve). In order to observe these differ-
ences, the results are compared with Dna samples with an 
unchanged copy number of templates for each of the ampli-
fied fragments.
to present the results in figures and to mitigate the influ-
ence of differences in the amplification efficacy of partic-
ular samples, the highest values of peaks are determined, 
followed by calculating the ratio of the analysed peak to the 
reference peak in each reaction. subsequently, the ratios 
obtained are divided by the average value of the peak ratio 
of all 4 control samples with an unchanged copy number 
which allows the results to be normalized. the assump-
tion is made that the peak height ratio should be 0.5× for 
samples with deletion (n copies) and 1.5× for samples with 








































Fig. 1  Conceptual graph presenting an outline of the method. a Melt-
ing profile containing examples of possible genotypes. Green curve 
represents wild type sample, blue curve represents sample with 
amplification of the target amplicon, red curve represents a sample 
with deletion of the target amplicon, purple curve represents a sample 
with point mutation in the target amplicon. b Graph results. Columns 
represent normalised peak height ratio of the target amplicon to the 
reference amplicon calculated for each sample (colour figure online)
538 Hum Genet (2014) 133:535–545
1 3
for wild type samples (2n copies). the comparison of the 
ratio obtained for the unknown samples with the ratio of 
samples with an unchanged number of copies allows sam-
ples with possible rearrangements of the analysed gene to 
be determined (Fig. 1b).
For Dna samples with large rearrangements (both large 
deletions and large amplifications), the standard peak height 
ratio observed in the control sample (with a normal number 
of copies for both amplicons) is distorted. a clear difference 
can be observed in the peak ratio for samples in which the 
analysed fragment undergoes deletion or amplification. the 
difference stems from the change in the initial amount of the 
template of the analysed gene compared with the amount of 
the reference amplicon template. the analysis should pref-
erably be performed during the exponential phase of PCr 
when the efficiency depends mostly on the initial amount of 
template and when no reagent in the reaction mixture was 
depleted. therefore, data for the melting peak height ratio 
calculations are obtained after the 30th cycle.
Detection of small sequence changes was performed as 
in the standard HrM. the area of analysis was narrowed 
only to the target amplicons. Performing a full PCr reac-
tion (up to the 40th cycle) enables a greater amount of PCr 
products to be achieved, which is beneficial for the detec-
tion of small mutations.
C-HrM sensitivity assessment
the sensitivity of the method was assessed through the 
analysis of mixed Dna samples with different proportions 
of a deletion carrier (C) and wild type control (W). the 
proportions in each reaction were as follows: C 1:W 0; C 
0.75:W 0.25; C 0.5:W 0.5; C 0.25:W 0.75; C 0:W 1. the 
assessment was based on the assay for the DMD exon 45. 
all samples were analysed in triplicates in the presence of 
four wild type controls for normalization.
Results
the study enabled us to demonstrate the usefulness of the 
new C-HrM method in the detection of previously identi-
fied small mutations in corresponding amplified fragments 
with a simultaneous detection of their Cnvs (tables 1, 2). 
the mean of all normalized peak height ratios for 72 wild 
type control samples was 0.9944 with standard error of the 
mean of 0.090033. assuming that ratios for samples with 
deletion (n copies) should be 0.5× and for samples with 
duplication (3n copies) should be 1.5×, we adopted the 
standard deviation from the control samples and created 
an approximate scale to assign the examined sample to one 
of the groups with: ratio below 0.60 indicating a deletion, 
ratio between 0.9 and 1.1 indicating the unchanged copy 
number in relation to the control sample, and ratio above 
1.4 indicating an amplification. Obtaining equivocal values 
(outside the adopted ranges) for any of the samples may 
be caused by an inappropriate reaction design (unspecific 
primer binding etc.), the poor quality of a sample (degraded 
Dna, presence of inhibitors etc.) or pipetting errors. How-
ever, it may also indicate possible mosaics. If subsequent 
analyses give similar results, further investigation using 
other quantitative methods should be applied.
the interpretation of the results of the analyses for genes 
located on the sex chromosomes (including the DMD gene) 
should be carried out with respect to an individual’s gender. 
this is caused by the difference in the base copy number of 
the gene for men and women. In the case of the DMD gene 
studies an unaffected male has one copy of the DMD gene, 
a male duplication carrier has two copies of the amplified 
fragment (the result of analyses is the same as in the case of 
healthy women), while a male with a deletion of the studied 
fragment is devoid of any allele (hence the lack of amplifi-
cation). Figures 2 and 3 present examples of the results of 
individual analyses for exon 45 of the DMD gene and exon 
15 of the APC gene. example results for other exons are 
included in the supplementary Material.
the DMD gene studies
among the 50 examined patients the results were entirely 
consistent (100 %) with those that had been obtained previ-
ously using other methods. all the mutations detected by 
previous methods were observed and there were no false 
positive results. In addition, all genotypes of the common 
intronic polymorphism rs1379871 in the amplicon for 
exon 49 were also distinguished. Detailed information on 
the types of the detected mutations is given in table 1. an 
example result for exon 45 is presented in Fig. 2. analysis 
of 72 unaffected individuals from the control group did not 
give any false positive results. In addition, the presence of 
the DMD gene on the X chromosome allowed the gender 
of each of the controls to be determined on the basis of the 
relative copy number (on the same principle as for a Cnv 
mutation carrier).
the APC gene studies
the results of analyses conducted on fragments of exons 9, 
14, 15 of the APC gene correspond completely (100 %) with 
the results of previous studies. all the previously identified 
mutations in these fragments, both small changes and Cnv, 
were observed during C-HrM. analysis of the 72 unaffected 
individuals from the control group did not result in obtaining 
any false positive results. Detailed information on the types 
of detected mutations is given in table 2. an example result 
for a fragment of exon 15 is presented in Fig. 3.
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C-HrM sensitivity
the C-HrM analysis of different proportions of the muta-
tion carrier and wild type control demonstrated the level 
of sensitivity of the method. the results are presented as 
a linear regression with R2 of 0.9974 (Fig. 4). taking into 
consideration the scale we adopted, theoretically it could 
be possible to distinguish a sample containing only 17.3 % 
of Dna with the deleted allele which implies that C-HrM 
has the capability to detect mosaics.
Discussion
the detection of mutations in genetic material is a major 
challenge for both genetic diagnostics and molecular 
genetic studies. screening methods allow the costs of anal-
ysis to be decreased by reducing the amount of sequencing. 
Commonly used methods of screening for mutations ena-
ble the detection of only one type of mutation in a single 
analysis. the aim of our study was to validate the invented 
method for the simultaneous detection of Cnvs and small 
mutations.
the comparative-HrM method we developed allows a 
simultaneous detection of small mutations and Cnvs in the 
analysed fragments. this new approach has the advantage 
over previously employed methods for mutation screening 
in that it makes it possible to detect both types of muta-
tion during a single analysis. screening methods such as 
HrM, Ha, ssCP and direct PCr product sequencing fail 
in the case of Cnvs. Our C-HrM method may turn out to 
be an attractive alternative to the MlPa and quantitative-
PCr (qPCr) that are currently, widely used in diagnostics 
for detecting Cnvs, especially taking into consideration 
its simplicity and easy application. In contrast to qPCr 
methods in which quantification is based on amplification 
curve data, our method uses peak height ratio calculations 
obtained during melting analysisto determine the relative 
copy number. this opens up the possibility of its applica-
tion in cases where the qPCr fails due to e.g. low amplifi-
cation efficiency.
the C-HrM method does not require any other reagents 
apart from those used in the standard HrM and the anal-
ysis takes only slightly more time, being extended by the 
time required for the additional melting process, however, 
it does not need any further processing and separation of 
the PCr products as in MlPa. Moreover, there is no need 
for any special reagents (unlike the case of MlPa) or for 
a significant number of samples with known parameters to 
create a standard curve (unlike in qPCr), and the method 
itself may be employed in every laboratory equipped with 
an HrM device. the costs of the analysis are almost equal 




Previous results  
for the APC gene
C-HrM results for  
exon 9 of the APC gene
C-HrM results for  
exon 14 of the APC gene
C-HrM results for  
exon 15 of the APC gene
Correspondence 
of the results
a1 Deletion of exons 11-14 Wt Deletion of exon 14 Wt Full
a2 Deletion of whole  
aPC gene
Deletion of exon 9 Deletion of exon 14 Deletion of exon 15 Full
a3 Deletion of whole  
aPC gene
Deletion of exon 9 Deletion of exon 14 Deletion of exon 15 Full
a4 c.1100_1101delCt c.1100_1101delCt Wt Wt Full
a5 c.1100_1101delCt c.1100_1101delCt Wt Wt Full
a6 c.1879_1882delaaCa Wt c.1879_1882delaaCa Wt Full
a7 c.1744G>t Wt c.1744G>t Wt Full
a8 c.1779G>a Wt c.1779G>a Wt Full
a9 c.1829dela Wt c.1829dela Wt Full
a10 c.2932C>t Wt Wt c.2932C>t Full
a11 c.2805C>G Wt Wt c.2805C>G Full
a12 c.2802–2805delttaC Wt Wt c.2802–2805delttaC Full
a13 c.2805C>a Wt Wt c.2805C>a Full
a14 c.2802–2805delttaC Wt Wt c.2802–2805delttaC Full
a15 c.2802–2805delttaC Wt Wt c.2802–2805delttaC Full
a16 c.2805C>G Wt Wt c.2805C>G Full
a17 c.2805C>G Wt Wt c.2805C>G Full
a18–50 Wt Wt Wt Wt Full
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to those for the standard HrM since they are increased 
only by the cost of additional primers. C-HrM allows the 
study of larger amplicons (in our assay up to 249 bp) than 
those recommended for qPCr (80–150 bp) which also 
reduces expenses and number of analyses (D’Haene et al. 
2010). In addition, the method seems to be unaffected by 
the fluctuations of the template concentration (the amount 
of template has no influence on the peak ratio as both frag-
ments are amplified in one reaction tube).
a clear advantage of the MlPa method over C-HrM 
is that MlPa can detect copy number alteration of mul-
tiple (>20) loci in a single assay (schouten et al. 2002). 
However, it does not allow the screening of these loci 
for small mutations and their separate screening must be 
applied. Furthermore, MlPa requires additional process-
ing and the use of capillary electrophoresis equipment 
which is unnecessary for C-HrM analysis. We are confi-
dent that in the future it will be possible to design specific 
assays for whole coding sequences of most disease causing 
genes enabling C-HrM performance.
C-HrM is not only useful in the detection of Cnvs but 
is also equally effective as a standard HrM in the screening 
for small mutations. Our observations indicate that an addi-













































Sample No. 1 2 3 4 5 6 7 8 9 10 11 12
Reference amplicon height maximum 11,86 10,28 3,088 9,984 4,172 3,845 5,33 5,826 3,955 6,326 4,223 3,82
Target amplicon height maximum 0,068 0,073 1,921 0,069 3,632 3,536 2,538 2,823 3,563 3,047 3,698 3,072
Peak height ratio 0,006 0,007 0,622 0,007 0,871 0,92 0,476 0,485 0,901 0,482 0,876 0,804







Fig. 2  the examination of the DMD gene exon 45. an example of 
detection of small mutations and Cnvs present in exon 45. a Melting 
profile of examined samples after the 30th cycle. b Melting profile of 
examined samples after the 40th cycle. c Peak height ratio calcula-
tions based on the results from melting after the 30th cycle. d Graph 
results. Blue columns represent samples with deletion of 1 allele, red 
columns represent hemizygotes with deletion (resulting in a lack of 
amplification of the target amplicon), green columns represent wild 
types, pink columns represent samples with small mutations (colour 
figure online)
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of the HrM method in detecting small mutations. In 
the analysed fragments of genes, in multiplex reactions 
using the reference fragments, we observed all the previ-
ously detected small mutations (tables 1, 2). although 
we observed them during the melting process after 30 and 
after 40 cycles, a larger amount of the product is more ben-
eficial for small mutations that are more difficult to distin-
guish after the 30th cycle. therefore, we prefer perform-
ing additional amplification cycles followed by an analysis 
of samples with respect to the presence of small sequence 
changes.
During the validation of the method for each of the 
tested Dna sample a series of three separate analyses were 
performed. Fluctuations in the peak height ratios in subse-
quent analyses of each sample ranged between 5 and 10 %. 
However, they did not affect the consistency of the results 
obtained. all three repeated analyses for each sample indi-
cated consistent results and each time it was possible to 
easily distinguish a sample with deletion/duplication from 
a sample with an unchanged number of copies. Most proba-
bly, these fluctuations are not due to the imperfection of the 
method but are rather associated with minimal differences 
in the composition of each of the reaction mixtures (includ-
ing the concentration of each primer) and the amount of the 
initial template in each repetition, both resulting from the 
inaccuracy of manual pipetting techniques. these results 
may suggest 100 % specificity of the method. nevertheless, 
it must be taken into account that the development of the 
methodology was conducted on high quality Dna sam-




























Sample No. 1 2 3 4 5 6 7 8 9 10 11 12
Reference amplicon height maximum 5,976 6,204 5,134 5,046 7,038 7,202 6,817 6,608 6,648 6,322 6,119 6,393
Target amplicon height maximum 2,48 2,659 3,635 3,56 2,538 2,714 2,637 2,486 2,55 2,451 2,668 2,273
Peak height ratio 2,41 2,333 1,412 1,417 2,773 2,654 2,585 2,658 2,607 2,579 2,293 2,813






Fig. 3  the examination of the APC gene exon 15. an example 
of detection of small mutations and Cnvs present in a fragment of 
exon 15. a Melting profile of examined samples after the 30th cycle. 
b Melting profile of examined samples after the 40th cycle. c Peak 
height ratio calculations based on the results from melting after the 
30th cycle. d Graph results. Blue columns represent samples with 
deletion of 1 allele, green columns represent wild types, pink columns 
represent samples with small mutations (colour figure online)
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analysis. C-HrM (as other quantification analyses) is sen-
sitive to the degree of degradation and the quality of the 
genetic material used for the research. Despite the fact that 
in our group of patients we did not obtain any false positive 
results, their occurrence in other groups cannot be ruled 
out. In the case of an analysis of a larger cohort of samples 
with various degrees of quality we do not exclude the pos-
sibility of obtaining false results.
the key factor for successful C-HrM analysis, as for 
qPCr, is the specificity of the designed primers (D’Haene 
et al. 2010). apart from high specificity, primers must be 
able to amplify in a multiplex reaction, therefore a uniform 
annealing temperature is required. In addition, there has to 
be lack of non-specific interactions between all 4 primers, 
since non-specifically binding primers may lower the PCr 
efficiency. amplification efficiency is higher for shorter 
products, thus both amplicons should be of a similar size. 
Furthermore, for proper small mutation screening, target 
and reference melting peaks cannot overlap, thus products 
must have different melting temperatures. Most likely, it 
will be difficult to find a universal reference amplicon as 
a control for all C-HrM analyses. In our study we used 
reference amplicons based on a two highly conserved gene 
fragments, and one worked with five of the six studied 
amplicons (table 3).
the results of C-HrM for samples with small muta-
tions may be inaccurate due to the change of shape of 
the target amplicon peak caused by a different melting 
behaviour in heterozygous samples (Figs. 2, 3). a simi-
lar situation appears in the case of result interpretation for 
amplicons containing common polymorphisms (as in the 
amplicon for exon 49 of the DMD gene, designed by us, 
which encompasses rs1379871). However, this does not 
reduce the detectability of the method. there is no need 
to calculate ratios for samples with small mutations so we 
recommend analysing results in terms of small mutations 
at first, and subsequently calculating peak height ratios for 
other samples where no small mutations were detected. 
this approach not only overcomes problems with incorrect 
results but also reduces the number of samples that require 
calculations. this also applies to the heterozygous samples, 
since heterozygosity implies the presence of at least two 
alleles, thus lack of alteration. Problems with calculations 
would concern only rare cases of amplifications containing 
heterozygous polymorphic sites. However, our studies indi-
cate that even such cases can be properly diagnosed due to 
the smaller impact of the imbalanced alleles on the shape 
of the peak (66–33 % in the alleles ratio). nevertheless, to 
correctly validate the method, for rs1379871 in exon 49 of 
the DMD gene we used two sets of control samples: wild 
type controls for the normalization of wild type samples 
and heterozygous controls for the normalization of het-
erozygous samples. In the future it will also be possible to 
use the areas of individual peaks instead of their maximum 
height to calculate ratios of the target amplicon to the ref-
erence amplicon. this could increase the accuracy of the 
method and overcome problems with the calculation for 
amplicons including polymorphic sites.
Comparative-HrM is a rapid, inexpensive, high 
throughput method to prescreen for small mutations and 
large rearrangements in a single run. this novel and reli-
able approach uses melting peak height ratio calculations 
instead of an amplification curve for relative quantifica-
tion. there is no need for electrophoretic separation or 
Fig. 4  sensitivity of C-HrM in 
Cnv detection. the sensitiv-
ity of the C-HrM method was 
assessed by mixing different 
proportions of the Dna from 
female deletion carrier of the 
DMD exon 45 and wild type 
control (a). the results are 
presented as a linear regression 
with R2 of 0.9974 (b). taking 
into consideration the scale we 
adopted, theoretically it could 
be possible to distinguish a 
sample with only 17.3 % of 




Carrier (C) :Wild type (W) C 1 : W 0 C 0,75 : W 0,25 C 0,5 : W 0,5 C 0,25 : W 0,75 C 0 : W 1
Predicted peak height ratio 0,5 0,625 0,75 0,875 1
Obtained peak height ratio (Mean) 0,558 0,686 0,828 0,941 1,052
Standard deviation 0,017 0,023 0,008 0,017 0,048
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additional handling, since the whole analysis is conducted 
in a close tube system. the method could be a useful tool 
for simultaneous screening for small Dna mutations and 
Cnvs prior to characterization by sequencing or array-
comparative genomic hybridization. It enabled both types 
of mutations to be revealed rapidly in a large series of sam-
ples with 100 % accuracy.
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